129 related articles for article (PubMed ID: 10572200)
1. The use of MTDSC to assess the amorphous phase content of a micronized drug substance.
Guinot S; Leveiller F
Int J Pharm; 1999 Dec; 192(1):63-75. PubMed ID: 10572200
[TBL] [Abstract][Full Text] [Related]
2. Use of heat of adsorption to quantify amorphous content in milled pharmaceutical powders.
Alam S; Omar M; Gaisford S
Int J Pharm; 2014 Jan; 459(1-2):19-22. PubMed ID: 24315924
[TBL] [Abstract][Full Text] [Related]
3. The detection of amorphous material in a nominally crystalline drug using modulated temperature DSC--a case study.
Saklatvala R; Royall PG; Craig DQ
Int J Pharm; 1999 Dec; 192(1):55-62. PubMed ID: 10572199
[TBL] [Abstract][Full Text] [Related]
4. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of moisture uptake effects on the glass transitional behaviour of an amorphous drug using modulated temperature DSC.
Royall PG; Craig DQ; Doherty C
Int J Pharm; 1999 Dec; 192(1):39-46. PubMed ID: 10572197
[TBL] [Abstract][Full Text] [Related]
6. Using thermally stimulated current (TSC) to investigate disorder in micronized drug substance produced at different milling energies.
Forcino R; Brum J; Galop M; Sun Y
Pharm Res; 2010 Oct; 27(10):2234-41. PubMed ID: 20697781
[TBL] [Abstract][Full Text] [Related]
7. Rapid assessment of the structural relaxation behavior of amorphous pharmaceutical solids: effect of residual water on molecular mobility.
Miller DP; Lechuga-Ballesteros D
Pharm Res; 2006 Oct; 23(10):2291-305. PubMed ID: 16955371
[TBL] [Abstract][Full Text] [Related]
8. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry.
Mackin L; Zanon R; Park JM; Foster K; Opalenik H; Demonte M
Int J Pharm; 2002 Jan; 231(2):227-36. PubMed ID: 11755274
[TBL] [Abstract][Full Text] [Related]
9. The development of DMA for the detection of amorphous content in pharmaceutical powdered materials.
Royall PG; Huang CY; Tang SW; Duncan J; Van-de-Velde G; Brown MB
Int J Pharm; 2005 Sep; 301(1-2):181-91. PubMed ID: 16026947
[TBL] [Abstract][Full Text] [Related]
10. Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry.
Venkatesh GM; Barnett ME; Owusu-Fordjour C; Galop M
Pharm Res; 2001 Jan; 18(1):98-103. PubMed ID: 11336360
[TBL] [Abstract][Full Text] [Related]
11. Dynamic vapor sorption as a tool for characterization and quantification of amorphous content in predominantly crystalline materials.
Sheokand S; Modi SR; Bansal AK
J Pharm Sci; 2014 Nov; 103(11):3364-3376. PubMed ID: 25213429
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
[TBL] [Abstract][Full Text] [Related]
13. The potential of high speed DSC (hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples.
Saunders M; Podluii K; Shergill S; Buckton G; Royall P
Int J Pharm; 2004 Apr; 274(1-2):35-40. PubMed ID: 15072780
[TBL] [Abstract][Full Text] [Related]
14. Quantification of low levels of amorphous content in sucrose by hyperDSC.
Lappalainen M; Pitkänen I; Harjunen P
Int J Pharm; 2006 Jan; 307(2):150-5. PubMed ID: 16288841
[TBL] [Abstract][Full Text] [Related]
15. Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption.
Müller T; Schiewe J; Smal R; Weiler C; Wolkenhauer M; Steckel H
Eur J Pharm Biopharm; 2015 May; 92():102-11. PubMed ID: 25779351
[TBL] [Abstract][Full Text] [Related]
16. Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin.
Feng T; Pinal R; Carvajal MT
J Pharm Sci; 2008 Aug; 97(8):3207-21. PubMed ID: 17990307
[TBL] [Abstract][Full Text] [Related]
17. An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry.
He R; Craig DQ
J Pharm Pharmacol; 2001 Jan; 53(1):41-8. PubMed ID: 11206191
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the degree of disorder in micronized salbutamol sulfate using moisture sorption analysis.
Gorny M; Jakobs M; Mykhaylova V; Urbanetz NA
Drug Dev Ind Pharm; 2007 Mar; 33(3):235-43. PubMed ID: 17454056
[TBL] [Abstract][Full Text] [Related]
19. Quantification of low levels of amorphous content in crystalline celecoxib using dynamic vapor sorption (DVS).
Sheokand S; Modi SR; Bansal AK
Eur J Pharm Biopharm; 2016 May; 102():77-86. PubMed ID: 26948976
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
